What to know
- A recording of this webinar is available below. Visit CDC TRAIN to get free continuing education (CE) for this webinar.
- The TRAIN course registration code is ZOHUwebcast.
Webinar details
Presentation Topic
- Food Adulteration: Understanding the Largest Case of Intentional Adulteration: Melamine In Animal Food and Infant Formula
Presenter
- Renate Reimschuessel VMD, Ph.D., Retired, Director of FDA's Veterinary Laboratory Investigation and Response Network Food and Drug Administration, Center for Veterinary Medicine, Rreimsch8888@gmail.com
Get email updates
Sign up for our email newsletter below.
Continuing Education (CE)
Visit CDC Train to receive free CE for the Webcast and Web-on-demand courses. Use 'zohu' to search for all available ZOHU Call courses. Follow these steps below:
- Register for and complete the course.
- Pass the post-assessment at 80%.
- Complete the evaluation.
- Visit Your Learning to access your certificates and transcript.
Webcast (Live)
- Course Name: WC5035-061726
- Start Date: June 17, 2026
- End Date: July 20, 2026
- Registration Code: ZOHUwebcast
Web-on-Demand (Recording)
- Course Name: WD5035R-061726
- Start Date: July 21, 2026
- End Date: July 21, 2029
Objectives
By the end of this webinar, participants will be able to:
- Identify at least one impact the One Health issue has on human, animal, or environmental health.
- Identify at least one One Health approach strategy to help prevent a public health threat.
- Identify at least one One Health approach strategy to help detect a public health threat.
- Identify at least one One Health approach strategy to help respond to, or prepare for, a public health threat.
- List two ways to improve collaborative practice across the public healthcare team.
Disclosures
In compliance with continuing education requirements, all planners and presenters must disclose all financial relationships, in any amount, with ineligible companies over the previous 24 months as well as any use of unlabeled product(s) or products under investigational use.
CDC, our planners, and presenters wish to disclose they have no financial relationship(s) with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Content will not include any discussion of the unlabeled use of a product or a product under investigational use.
CDC did not accept commercial or in-kind support for this activity.